Adagene Inc. (NASDAQ:ADAG – Free Report) – Investment analysts at HC Wainwright upped their FY2024 EPS estimates for Adagene in a research note issued on Monday, January 27th. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($0.64) for the year, up from their prior forecast of ($0.78). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Adagene’s current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Adagene’s FY2025 earnings at ($0.74) EPS, FY2026 earnings at ($0.77) EPS, FY2027 earnings at ($1.33) EPS and FY2028 earnings at ($1.26) EPS.
Adagene Stock Performance
Shares of Adagene stock opened at $1.85 on Wednesday. The business has a 50-day moving average price of $2.02 and a two-hundred day moving average price of $2.39. Adagene has a 1-year low of $1.74 and a 1-year high of $3.85.
Institutional Investors Weigh In On Adagene
About Adagene
Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.
Featured Articles
- Five stocks we like better than Adagene
- What is a Dividend King?
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- The 3 Best Blue-Chip Stocks to Buy Now
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- How to Calculate Stock Profit
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Adagene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagene and related companies with MarketBeat.com's FREE daily email newsletter.